JAK1 and atopic eczema: Upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, has been approved for the treatment of moderate-to-severe atopic dermatitis based on phase 3 randomized trials demonstrating significant clinical improvement in disease severity and pruritus compared with placebo [7].